NCT05475834View on ClinicalTrials.gov

Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

August 7, 2022

Study Completion Date

August 7, 2022

Conditions
Healthy Male Volunteers
Interventions
DRUG

SIM0417

Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.

Trial Locations (1)

250000

Shandong First Medical University, Jinan

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY